Cargando…

Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi

INTRODUCTION: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumari, Sushma, Saroj, Usha, Verma, Ashwini, Kumar, Abhay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810935/
https://www.ncbi.nlm.nih.gov/pubmed/36618231
http://dx.doi.org/10.4103/jfmpc.jfmpc_727_22
Descripción
Sumario:INTRODUCTION: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG antibodies are developed either by natural infection from SARS-CoV-2 or by vaccination against COVID-19. The persistence of IgG antibodies allows identification of the people who have been infected in the past, recovered from illness, and possibly become immune. 7 IgG detection and other serological assays will play an important role in research and surveillance. AIMS AND OBJECTIVE: The objective of the study is to assess anti-SARS-CoV-2 IgG titre among blood donors and to assess the decreasing incidence of COVID-19 in the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand. MATERIALS AND METHODS: An observational, cross-sectional study was conducted at the department of blood bank, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand over a period of 2 months and 14 days from 06 February 2021 to 20 April 2021 who donated at least one unit of blood. RESULTS: This study recorded a greater number of male donors with B+ blood group. The anti-SARS-CoV-2 titre were mostly young adults between 18 and 31 years of age. CONCLUSION: Seroprevalence was high in males having blood group B+ between 18 and 32 years of age.